文献速递角膜与眼表疾病小儿眼科与斜弱视

儿童圆锥角膜患者的角膜胶原交联治疗

Corneal collagen cross-linking in paediatric patients affected by keratoconus.
PubMed 文献 · Br J Ophthalmol · 2017-06-27

这项前瞻性队列研究纳入43名儿童患者的52只进展性圆锥角膜眼,采用传统角膜胶原交联(CXL)治疗,即0.1%核黄素-20%右旋糖酐浸泡30分钟,并在30分钟紫外线A照射(3 mW/cm2)期间持续滴注。治疗后2年最大角膜曲率(K-max)显著下降,内皮细胞密度保持稳定;作者认为CXL是避免儿童圆锥角膜进展的有效治疗。

要点

  • 治疗后2年K-max从59.30±7.08降至57.07±6.46(p<0.001)。
  • K-max≥60 D的25只眼亚组2年时K-max从64.94±4.99 D降至62.25±4.42 D(p<0.001)。
  • 内皮细胞密度2年保持稳定,从2800±363变为2736±659 cells/mm2(p=0.90)。

核心结论

  • 作者认为CXL是避免儿童患者圆锥角膜进展的有效治疗,且该操作安全,能成功稳定以地形图K-max大于60 D为特征的较晚期圆锥角膜。

研究设计与样本

  • 前瞻性队列研究,纳入43名进展性圆锥角膜儿童患者的52只眼,采用传统CXL技术:0.1%核黄素-20%右旋糖酐溶液浸泡30分钟,并在30分钟紫外线A照射(3 mW/cm2)期间持续滴注。
  • 术后测量视力结局、地形图角膜曲率、最大角膜曲率(K-max)、屈光性散光、分界线和内皮细胞密度。

主要发现

  • 治疗2年后K-max从59.30±7.08显著降至57.07±6.46(p<0.001)。
  • 裸眼视力从0.59±0.41 LogMAR改善至0.46±0.33 LogMAR(p=0.06),最佳眼镜矫正视力从0.17±0.11 LogMAR改善至0.15±0.12 LogMAR(p=0.17)。
  • 25只眼K-max≥60 D,该亚组2年时K-max从64.94±4.99 D显著降至62.25±4.42 D(p<0.001)。
  • CXL治疗分界线平均为249±74 µm,与K-max变平无显著相关性(Spearman r=0.019,p=0.899)。
  • 术后2年内皮细胞密度保持稳定,从2800±363变为2736±659 cells/mm2(p=0.90)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To evaluate the effectiveness of corneal collagen cross-linking (CXL) in paediatric patients. METHODS: Fifty-two eyes of 43 paediatric patients with progressive keratoconus were enrolled in a prospective cohort study. Corneal CXL was performed using a conventional technique with instillation of 0.1% riboflavin solution containing dextran 20% for 30 min during the soaking phase and during the 30 min ultraviolet A irradiation (3 mW/cm2). Visual outcomes, topographic keratometry, maximum keratometry (K-max), refractive astigmatism, demarcation line and endothelial cell density were measured postoperatively. RESULTS: A significant decrease of K-max from 59.30±7.08 to 57.07±6.46 (p<0.001) was observed 2 years after treatment. Uncorrected visual acuity improved from 0.59±0.41 LogMAR (logarithm of the minimum angle resolution) to 0.46±0.33 LogMAR (p=0.06) 2 years after the procedure, while best spectacle corrected visual acuity improved from 0.17±0.11 LogMAR to 0.15±0.12 LogMAR (p=0.17). Twenty-five eyes had K-max values of 60 dioptres (D) or greater. In this subgroup, K-max significantly decreased from 64.94±4.99 D to 62.25±4.42 D at 2 years (p<0.001). The demarcation line of the CXL treatment had a mean value of 249±74 µm and did not show a significant correlation with K-max flattening (Spearman r=0.019, p=0.899). Endothelial cell density remained stable 2 years after the procedure, changing from 2800±363 to 2736±659 cells/mm2 (p=0.90). CONCLUSION: CXL is an effective treatment for avoiding keratoconus progression in paediatric patients. The procedure is safe and successful in stabilising keratoconus in eyes with more advanced forms of the disease, characterised by topographic K-max values greater than 60 D.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Knutsson KA, Paganoni G, Matuska S, et al. Corneal collagen cross-linking in paediatric patients affected by keratoconus. Br J Ophthalmol. 2017. PMID: 28655729. doi:10.1136/bjophthalmol-2016-310108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。